A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced Solid Tumors

(2010) P. J. Rosen et al.   CLINICAL CANCER RESEARCH

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

(2010) J. P. Eder et al.   CLINICAL CANCER RESEARCH

Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors

(2010) M. S. Gordon et al.   CLINICAL CANCER RESEARCH

Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors

(2010) B. J. Scott et al.   NEURO-ONCOLOGY

Primary central nervous system lymphoma

(2009) Lauren E Abrey   CURRENT OPINION IN NEUROLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value

(2009) Roberto Garcia-Navarrete et al.   JOURNAL OF NEURO-ONCOLOGY

EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts

(2009) B. Lal et al.   MOLECULAR CANCER THERAPEUTICS

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

(2009) Eudocia C. Quant et al.   NEURO-ONCOLOGY

Angiogenesis as a Therapeutic Target in Malignant Gliomas

(2009) A. S. Chi et al.   ONCOLOGIST

Prognostic significance of c-Met expression in glioblastomas

(2008) Doo-Sik Kong et al.   CANCER

Development of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma Samples

(2008) K. Yoshimoto et al.   CLINICAL CANCER RESEARCH

Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177

(2008) Paul D. Brown et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

(2008) Dieta Brandsma et al.   LANCET ONCOLOGY

Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome

(2008) Kevin R. Kozak et al.   NEURO-ONCOLOGY

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE